Industry Insights: Behind the Scenes of BPS Bioscience Custom R&D
Explore how BPS Bioscience utilizes a scientist-driven, milestone-measured framework to de-risk custom R&D and screening projects for biopharma teams.
Human iPSC-Derived Sensory Neurons for Functional Sensory Biology and Pharmacology Research
Get an exclusive first look at BrainXell’s newly launched human iPSC-derived sensory neurons and learn how they enable reproducible, human-relevant models for sensory transduction, pharmacology, and ion channel research.
Industry Insights with Henry Zhu and BPS Bioscience
Henry Zhu, CEO of BPS Bioscience, reflects on 20 years of growth, innovation, and the company’s role in advancing drug discovery research.
Novel Applications of the Cellular Thermal Shift Assay (CETSA) Provide New Insights for Drug Discovery
Join AbbVie scientists Shitalben Patel and Jami R. Erickson as they showcase their innovative advancements, transforming CETSA® into a high-throughput flow-based platform and introducing new whole blood formats to elevate drug discovery.
Biomarkers from Bench to Bedside: Tools, Targets, and Translational Insights
Explore how new tools and strategies are advancing biomarker discovery, standardization, and translational research in oncology and beyond.
Using In Vitro Assays to Model Complex Biology with PhenoVista’s Assay Services
Learn about PhenoVista’s unique service offerings and how expertise in developing complex, in vitro studies to provide actionable and relevant data can help drive drug discovery forward.
Implementing the Colony-Forming Unit (CFU) Assay As a Potency Assay for Hematopoietic Cell Therapy Products
Join our webinar to learn how to effectively implement the CFU assay as a potency assay for hematopoietic cell therapy products.
#ExpertAnswers: Andrew Gaffney and Erin Knock on Neural Progenitor Cell Differentiation
Experts from STEMCELL Technologies answer questions from a webinar presenting an iPSC line and its differentiation into neural cells.
Fully Characterized, Standardized Human Induced Pluripotent Stem Cell Line and Ready-to-Use, High-Quality Neural Progenitor Cells for Downstream Differentiation Applications
On June 29, 2023, STEMCELL Technologies' Dr. Andrew Gaffney and Dr. Erin Knock presented on how to streamline PSC-related workflows using highly characterized induced pluripotent stem cells (iPSCs) and neural progenitor cells (NPCs), and how to differentiate these cells into a variety of cell types downstream. In this Q&A report, you can read their answers to questions asked by the audience. Answers have been edited for length and/or clarity.
Fully Characterized, Standardized Human Induced Pluripotent Stem Cell Line and Ready-to-Use, High-Quality Neural Progenitor Cells for Downstream Differentiation Applications
In this webinar, experts present a standardized human induced pluripotent stem cell line and its differentiation into neural cells for disease modeling and assay development.
